Close Menu

NEW YORK – Lynk Pharmaceuticals, a clinical-stage pharmaceutical company in Hangzhou, China, has inked an exclusive licensing pact with Kobe University and Riken Research Institute in Japan to develop RAS inhibitors with a novel mechanism of action.

Under the collaboration, Lynk will use its chemistry and drug design expertise and build on Kobe University and Riken's early structural biology and screening research to advance drugs that target a broader range of RAS mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.